4 completed, 2 terminated, 1 recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow MLN1117: new trials by email Literature Review of MLN1117 trials Research Report on MLN1117
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer Sapanisertib, Serabelisib, Paclitaxel - Endometrial Cancer | Phase 2 | Recruiting | Faeth Therapeutics | 40 | 2024-12-12 | 2025-12-24 |
| Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors paclitaxel, TAK-228, TAK-117 - Advanced Solid Tumor | Phase 1 | Completed | Avera McKennan Hospital & University Health Center | 19 | 2017-07-06 | 2024-07-26 |
| MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Everolimus, MLN0128, MLN1117 - Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 96 | 2016-06-30 | 2021-11-19 |
| A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer Paclitaxel, Sapanisertib, MLN1117 - Endometrial Neoplasms | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 241 | 2016-04-01 | 2021-11-24 |
| MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma MLN1117, TAK-659, Alisertib - Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 32 | 2015-10-15 | 2019-09-20 |
| Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer Docetaxel, TAK-117 - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Millennium Pharmaceuticals, Inc. | 14 | 2015-06-03 | 2018-02-07 |
| A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies TAK-228, TAK-117 - Advanced Nonhematologic Malignancies | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 101 | 2013-06-28 | 2019-10-30 |
Endometrial Neoplasms (2) · Carcinoma, Endometrioid (1) · Carcinoma, Non-Small-Cell Lung (1) · Clear-cell metastatic renal cell carcinoma (1) · Genital Diseases (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Millennium Pharmaceuticals, Inc. (5) · Avera McKennan Hospital & University Health Center (1) · Faeth Therapeutics (1)
United States (7) · Spain (4) · Canada (3) · United Kingdom (3) · Italy (2) · Netherlands (2) · Australia (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Norway (1) · Poland (1)
2014 (2), 2015 (2)